IGI Laboratories (IG) 5.83 $IG
IGI Laboratories Announces Second Quarter 2014 Results
PR Newswire - Thu Jul 24, 3:02PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic drug development and manufacturing company, announced its financial results for the second quarter ended June 30, 2014.
IGI Laboratories, Inc. Announces Change To Its Board Of Directors
PR Newswire - Thu Jul 24, 3:02PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has accepted Damian Finio's resignation from its Board of Directors. Mr. Finio has accepted a senior level finance position at a pharmaceutical company, and under the terms of his acceptance of his new position, Mr. Finio will be unable to continue in his role as Director for IGI Laboratories, Inc. The effective date of his resignation will be August 11, 2014. The Company has begun a search to replace Mr. Finio on its Board of Directors.
IGI Laboratories To Hold Conference Call For 2nd Quarter 2014 Results
PR Newswire - Fri Jul 18, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 24, 2014 to discuss the 2nd quarter 2014 results.
IGI Laboratories concludes public offering at USD5.00 per share
M2 - Thu Jul 03, 5:52AM CDT
Topical drug company IGI Laboratories (NYSE MKT:IG) reported on Wednesday the sale of an aggregate of 5,347,500 common stock in the public offering at USD5.00 per share.
IGI Laboratories Announces Closing Of Underwritten Offering Including Over-Allotment Option
PR Newswire - Wed Jul 02, 3:05PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced the closing of its previously announced underwritten public offering of shares of its common stock, including all 697,500 shares subject to the underwriters' over-allotment option. After giving effect to the exercise of the over-allotment option, the Company sold an aggregate of 5,347,500 shares of common stock in the offering at a public offering price of $5.00 per share. The net proceeds of the offering are expected to be approximately $25.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.
IGI Laboratories Added To The Russell 3000 Index
PR Newswire - Mon Jun 30, 1:08PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), a specialty generic topical pharmaceutical company, has been added as a member of the broad-market Russell 3000® Index after the equity markets closed on June 27 as Russell Investments reconstituted its comprehensive family of global indexes.
IGI Laboratories Prices $23.3 Million Underwritten Offering
PR Newswire - Fri Jun 27, 7:04AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced the pricing of its previously announced underwritten public offering of 4,650,000 shares of its common stock at a price to the public of $5.00 per share. IGI has also granted the underwriters a 30-day option to purchase up to an aggregate of 697,500 additional shares of common stock at the public offering price to cover over-allotments, if any. The gross proceeds of the offering will be $23,250,000, assuming no exercise of the overallotment option. The offering is expected to close on July 2, 2014, subject to customary closing conditions.
GI Laboratories to launch diclofenac sodium topical solution 1.5% product on 28 March 2015 upon settlement with Mallickrodt
M2 - Fri Jun 27, 5:04AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT: IG) on Thursday reported an agreement to settle a declaratory judgment action concerning its filing of an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w.
IGI Laboratories to launch public offering of common shares
M2 - Fri Jun 27, 4:59AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) said on Thursday that it intends to issue its common stock in an underwritten public offering.
IGI Laboratories Announces Public Offering Of Common Stock
PR Newswire - Thu Jun 26, 3:07PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced that it is offering shares of the Company's common stock in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
IGI Laboratories, Inc. Announces Joint Stipulation
PR Newswire - Thu Jun 26, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced that it has entered into an agreement with Mallinckrodt LLC, Mallinckrodt Inc., and Nuvo Research, Inc. (TSX: NRI) (together Mallickrodt) to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7, 2014.
Weakness Seen in Alcobra (ADHD): Stock Falls 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 7:35AM CDT
Alcobra stock fell nearly 7% last trading session, reversing its recent uptrend
IGI Laboratories' 18th and 19th ANDA on file with US FDA
M2 - Mon Jun 23, 5:30AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) reported on Friday the submission of two additional abbreviated new drug application (ANDA), the 18th and 19th, to the US Food and Drug Administration (FDA).
IGI Laboratories, Inc. Announces 18th and 19th ANDA Submissions
PR Newswire - Fri Jun 20, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted two additional abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions in 2014 to six, with seventeen submissions now pending at the FDA.
IGI Laboratories, Inc. Completes Its Seventh ANDA Filing For 2014 Under Joint Drug Development And Commercialization Agreement With Impax Laboratories, Inc.
PR Newswire - Fri Jun 20, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its seventh abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA). The seventh ANDA submission was in connection with an existing development, supply and marketing agreement with Impax Laboratories, Inc. (NASDAQ: IPXL). The agreement designates IGI Laboratories, Inc. (IGI) as the developer, manufacturer, and owner of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United States by Global Pharmaceuticals, Impax's generics division. In accordance with the agreement, Impax is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA.
IGI Laboratories files fourth ANDA with the US FDA in 2014
M2 - Fri Jun 20, 5:49AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) revealed on Thursday the submission of its fourth abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) in 2014.
IGI Laboratories, Inc. Announces Fourth ANDA Submission In 2014
PR Newswire - Thu Jun 19, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted another abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions in 2014 to four, with fifteen submissions now pending at the FDA.
IGI Laboratories, Inc. Announces Sixteenth ANDA Submission
PR Newswire - Wed Jun 18, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions to sixteen, with fourteen now pending at the FDA.
IGI Laboratories submits 15th ANDA to US FDA, with 13 pending approval and on file
M2 - Tue Jun 03, 4:35AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT: IG) disclosed on Monday the submission of its second abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) in 2014.
IGI Laboratories Announces Second Quarter 2014 Results
PR Newswire - Thu Jul 24, 3:02PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic drug development and manufacturing company, announced its financial results for the second quarter ended June 30, 2014.
IGI Laboratories, Inc. Announces Change To Its Board Of Directors
PR Newswire - Thu Jul 24, 3:02PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has accepted Damian Finio's resignation from its Board of Directors. Mr. Finio has accepted a senior level finance position at a pharmaceutical company, and under the terms of his acceptance of his new position, Mr. Finio will be unable to continue in his role as Director for IGI Laboratories, Inc. The effective date of his resignation will be August 11, 2014. The Company has begun a search to replace Mr. Finio on its Board of Directors.
IGI Laboratories To Hold Conference Call For 2nd Quarter 2014 Results
PR Newswire - Fri Jul 18, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 24, 2014 to discuss the 2nd quarter 2014 results.
IGI Laboratories concludes public offering at USD5.00 per share
M2 - Thu Jul 03, 5:52AM CDT
Topical drug company IGI Laboratories (NYSE MKT:IG) reported on Wednesday the sale of an aggregate of 5,347,500 common stock in the public offering at USD5.00 per share.
IGI Laboratories Announces Closing Of Underwritten Offering Including Over-Allotment Option
PR Newswire - Wed Jul 02, 3:05PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced the closing of its previously announced underwritten public offering of shares of its common stock, including all 697,500 shares subject to the underwriters' over-allotment option. After giving effect to the exercise of the over-allotment option, the Company sold an aggregate of 5,347,500 shares of common stock in the offering at a public offering price of $5.00 per share. The net proceeds of the offering are expected to be approximately $25.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.
IGI Laboratories Added To The Russell 3000 Index
PR Newswire - Mon Jun 30, 1:08PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), a specialty generic topical pharmaceutical company, has been added as a member of the broad-market Russell 3000® Index after the equity markets closed on June 27 as Russell Investments reconstituted its comprehensive family of global indexes.
IGI Laboratories Prices $23.3 Million Underwritten Offering
PR Newswire - Fri Jun 27, 7:04AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced the pricing of its previously announced underwritten public offering of 4,650,000 shares of its common stock at a price to the public of $5.00 per share. IGI has also granted the underwriters a 30-day option to purchase up to an aggregate of 697,500 additional shares of common stock at the public offering price to cover over-allotments, if any. The gross proceeds of the offering will be $23,250,000, assuming no exercise of the overallotment option. The offering is expected to close on July 2, 2014, subject to customary closing conditions.
GI Laboratories to launch diclofenac sodium topical solution 1.5% product on 28 March 2015 upon settlement with Mallickrodt
M2 - Fri Jun 27, 5:04AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT: IG) on Thursday reported an agreement to settle a declaratory judgment action concerning its filing of an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w.
IGI Laboratories to launch public offering of common shares
M2 - Fri Jun 27, 4:59AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) said on Thursday that it intends to issue its common stock in an underwritten public offering.
IGI Laboratories Announces Public Offering Of Common Stock
PR Newswire - Thu Jun 26, 3:07PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced that it is offering shares of the Company's common stock in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
IGI Laboratories, Inc. Announces Joint Stipulation
PR Newswire - Thu Jun 26, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced that it has entered into an agreement with Mallinckrodt LLC, Mallinckrodt Inc., and Nuvo Research, Inc. (TSX: NRI) (together Mallickrodt) to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7, 2014.
Weakness Seen in Alcobra (ADHD): Stock Falls 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 7:35AM CDT
Alcobra stock fell nearly 7% last trading session, reversing its recent uptrend
IGI Laboratories' 18th and 19th ANDA on file with US FDA
M2 - Mon Jun 23, 5:30AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) reported on Friday the submission of two additional abbreviated new drug application (ANDA), the 18th and 19th, to the US Food and Drug Administration (FDA).
IGI Laboratories, Inc. Announces 18th and 19th ANDA Submissions
PR Newswire - Fri Jun 20, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted two additional abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions in 2014 to six, with seventeen submissions now pending at the FDA.
IGI Laboratories, Inc. Completes Its Seventh ANDA Filing For 2014 Under Joint Drug Development And Commercialization Agreement With Impax Laboratories, Inc.
PR Newswire - Fri Jun 20, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its seventh abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA). The seventh ANDA submission was in connection with an existing development, supply and marketing agreement with Impax Laboratories, Inc. (NASDAQ: IPXL). The agreement designates IGI Laboratories, Inc. (IGI) as the developer, manufacturer, and owner of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United States by Global Pharmaceuticals, Impax's generics division. In accordance with the agreement, Impax is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA.
IGI Laboratories files fourth ANDA with the US FDA in 2014
M2 - Fri Jun 20, 5:49AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) revealed on Thursday the submission of its fourth abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) in 2014.
IGI Laboratories, Inc. Announces Fourth ANDA Submission In 2014
PR Newswire - Thu Jun 19, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted another abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions in 2014 to four, with fifteen submissions now pending at the FDA.
IGI Laboratories, Inc. Announces Sixteenth ANDA Submission
PR Newswire - Wed Jun 18, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions to sixteen, with fourteen now pending at the FDA.
IGI Laboratories submits 15th ANDA to US FDA, with 13 pending approval and on file
M2 - Tue Jun 03, 4:35AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT: IG) disclosed on Monday the submission of its second abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) in 2014.
